Age-dependent effects of SGLT2 inhibitors on stroke risk in geriatric patients with diabetes and atrial fibrillation
An erratum to this article was published (Cardiovasc Diabetol, 15 Mar 2025 ↗)
Authors' conclusion
The impact of SGLT2i on stroke risk varies significantly by age. While protective in younger patients, SGLT2i may increase stroke risk in those aged ≥ 90 years. These findings highlight the importance of age-specific considerations in prescribing SGLT2i for patients with AF and DM.
Study context
- Population
- Patients with atrial fibrillation (AF) and diabetes mellitus (DM), National Taiwan University Hospital database (2010–2020)
- Participants
- 9,669 patients
- Exposure
- SGLT2i users vs non-users, within age groups
- Outcome
- Stroke risk by age group
Methodological detailshistorical longitudinal follow-up, single hospital database
- Historical longitudinal follow-up
- Single hospital database
Main finding
As reported in the abstract
Stroke risk by age group (adjusted for CHA₂DS₂-VASc score and oral anticoagulant use)
SGLT2i users vs Non-usersHazard ratio (95% CI)P value
Age < 75 years
0.63(0.44–0.88)
P < 0.05Age 75-89 years
0.95(0.60–1.50)
Age ≥ 90 years
5.04(1.20–21.1)
P < 0.05- Interaction aged ≥ 90 years x SGLT2i use, HR (95% CI 1.49-27.40), P < 0.05
- 6.39
Observational data: associations, not effects.
Original publication
Age-dependent effects of SGLT2 inhibitors on stroke risk in geriatric patients with diabetes and atrial fibrillation. Cardiovasc Diabetol. Published 22 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →